Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase by K+-competitive binding with an IC50 of 1.0 μM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 32.00 | |
2 mg | In stock | $ 45.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 247.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 578.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase by K+-competitive binding with an IC50 of 1.0 μM. |
Targets&IC50 | K+ competitive binding:1.0 μM |
In vitro | Linaprazan (AZD0865) can inhibit the final step in acid secretion. Linaprazanreduced porcine renal Na+, K+-ATPase activity by 9 ± 2% [1]. |
In vivo | The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of Linaprazan would translate to a healing rate of 89% at 4 weeks [2]. |
Synonyms | AZD0865 |
Molecular Weight | 366.46 |
Formula | C21H26N4O2 |
CAS No. | 248919-64-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35 mg/mL (95.51 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Linaprazan 248919-64-4 Membrane transporter/Ion channel Potassium Channel inhibit AZD-0865 AZD 0865 Proton Pump AZD0865 Inhibitor inhibitor